⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CGTX News
Cognition Therapeutics, Inc. Common Stock
Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes
globenewswire.com
CGTX
Form 8-K
sec.gov
CGTX
Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045
globenewswire.com
CGTX
Cognition Therapeutics Participating in Upcoming Investor Conferences
globenewswire.com
CGTX
Form 8-K
sec.gov
CGTX
Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis
globenewswire.com
CGTX
Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
globenewswire.com
CGTX
Form 8-K
sec.gov
CGTX
Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update
globenewswire.com
CGTX
Cognition Therapeutics to Present at Needham Virtual Healthcare Conference
globenewswire.com
CGTX